Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Epperla N, et al. Among authors: devine sm. J Hematol Oncol. 2017 Jun 12;10(1):117. doi: 10.1186/s13045-017-0487-y. J Hematol Oncol. 2017. PMID: 28606176 Free PMC article.
Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model.
Mahmud N, Pang W, Cobbs C, Alur P, Borneman J, Dodds R, Archambault M, Devine S, Turian J, Bartholomew A, Vanguri P, Mackay A, Young R, Hoffman R. Mahmud N, et al. Exp Hematol. 2004 May;32(5):494-501. doi: 10.1016/j.exphem.2004.02.010. Exp Hematol. 2004. PMID: 15145218 Free article.
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR. Hallemeier CL, et al. Among authors: devine sm. Biol Blood Marrow Transplant. 2006 Jul;12(7):749-57. doi: 10.1016/j.bbmt.2006.03.009. Biol Blood Marrow Transplant. 2006. PMID: 16785064 Free article.
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. Hamadani M, et al. Among authors: devine sm. Biol Blood Marrow Transplant. 2008 Jul;14(7):783-9. doi: 10.1016/j.bbmt.2008.04.006. Biol Blood Marrow Transplant. 2008. PMID: 18541197 Free PMC article. Clinical Trial.
237 results